logo
logo

Valo Health Receives $110 Million In Funding From Koch Disruptive Technologies To Close Series B

Valo Health Receives $110 Million In Funding From Koch Disruptive Technologies To Close Series B

03/09/21, 12:59 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgboston
Money raised
$110 million
Round Type
series b
 Valo Health LLC (Valo), a technology company transforming the drug discovery and development process and seeking to accelerate the creation of life-changing drugs, today announced the final closing of its Series B at $300 million, including a $110 million investment from Koch Disruptive Technologies (KDT). This brings the overall funding of Valo to over $450 million.

Company Info

Company
Valo
Location
boston, massachusetts, united states
Additional Info
Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning computation to transform the drug discovery and development process. As a digitally native company, Valo is the first to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company's Opal Computational PlatformTM, a fully integrated, computational, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more, visit www.valohealth.com.